Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Royuela

Showing results (161-170 of 175) with videos related to

Pageof 18
Sort By:
Nutricion Hospitalaria|July 22, 2024
Cross-cultural validation and Spanish translation of the Boston Interview to evaluate severely obese patients seeking metabolic/bariatric surgeryMíriam Esther Pelayo Delgado, Stephanie Sogg, DeAnna L Mori, et al.
The Lancet. Oncology|September 27, 2020
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trialMariano Provencio, Ernest Nadal, Amelia Insa, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2021
Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatmentMariano Provencio, Roberto Serna-Blasco, Fabio Franco, et al.
BMC Cancer|September 1, 2021
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life dataLourdes Gutiérrez, Ana Royuela, Enric Carcereny, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 19, 2024
Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular LymphomaIsmael Fernández-Miranda, Lucía Pedrosa, Julia González-Rincón, et al.
Cancer Epidemiology|May 26, 2020
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimationMiguel Barquín, Virginia Calvo, Francisco García-García, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2022
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)Mariano Provencio, Roberto Serna-Blasco, Ernest Nadal, et al.
Endoscopy International Open|November 12, 2025
Effect of a distal attachment cuff on adenoma detection rate in screening colonoscopy: Randomized controlled trial in the Spanish populationAurora Burgos García, Alberto Herreros de Tejada, Carlos Ferre Aracil, et al.
Molecular Oncology|October 27, 2020
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trialAtocha Romero, Eloisa Jantus-Lewintre, Beatriz García-Peláez, et al.
Plos One|February 26, 2019
Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphomaJulia González-Rincón, Miriam Méndez, Sagrario Gómez, et al.
Pageof 18

Showing results (161-170 of 175) with videos related to

Sort By:
Pageof 18
Nutricion Hospitalaria|July 22, 2024
Cross-cultural validation and Spanish translation of the Boston Interview to evaluate severely obese patients seeking metabolic/bariatric surgeryMíriam Esther Pelayo Delgado, Stephanie Sogg, DeAnna L Mori, et al.
The Lancet. Oncology|September 27, 2020
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trialMariano Provencio, Ernest Nadal, Amelia Insa, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2021
Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatmentMariano Provencio, Roberto Serna-Blasco, Fabio Franco, et al.
BMC Cancer|September 1, 2021
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life dataLourdes Gutiérrez, Ana Royuela, Enric Carcereny, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 19, 2024
Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular LymphomaIsmael Fernández-Miranda, Lucía Pedrosa, Julia González-Rincón, et al.
Cancer Epidemiology|May 26, 2020
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimationMiguel Barquín, Virginia Calvo, Francisco García-García, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2022
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)Mariano Provencio, Roberto Serna-Blasco, Ernest Nadal, et al.
Endoscopy International Open|November 12, 2025
Effect of a distal attachment cuff on adenoma detection rate in screening colonoscopy: Randomized controlled trial in the Spanish populationAurora Burgos García, Alberto Herreros de Tejada, Carlos Ferre Aracil, et al.
Molecular Oncology|October 27, 2020
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trialAtocha Romero, Eloisa Jantus-Lewintre, Beatriz García-Peláez, et al.
Plos One|February 26, 2019
Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphomaJulia González-Rincón, Miriam Méndez, Sagrario Gómez, et al.
Pageof 18